2006 proposed fee schedule - American Society of Clinical Oncology

eporting requirements are discussed in further detail in
the interim final rule with comment, Medicare Program;
Manufacturer Submission of Manufacturer’s Average Sales
313
Price (ASP) Data for Medicare Part B Drugs and Biologicals,
that published on April 2, 2004 in the Federal Register
(69FR17935-17941).
The burden associated with these requirements is the
time and effort required by manufacturers of Medicare Part B
Drugs and biologicals to prepare and submit to the required
ASP data to CMS.
While these requirements are subject to the PRA, the
requirements are currently approved in OMB No. 0938-0921,
with a current expiration date of September 30, 2007.
We intend to revise this information collection to
include adequate instructions for manufacturers to report
the ASP, the WAC, and other data elements. These revisions
will be addressed in detail in a revised information
collection request in accordance with the Paperwork
Reduction Act of 1995.
We have submitted a copy of this proposed rule to OMB
for its review of the information collection requirements
described above. These requirements are not effective until
they have been approved by OMB.